A path toward clinical trial diversity
Minority and marginalized communities have historically been underrepresented in local and federal governments and in dozens of private sectors globally. Pharma is no different; there exists a steep chasm that drugmakers have yet to bridge concerning research and trials. The longer this gulf exists, the harder it becomes to address – the feelings of mistrust, resentment, and disenfranchisement only get harder to overcome with time.
Over the last decade, the pharmaceutical …
A path toward clinical trial diversity











![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)








![Safety-net dentistry restores human dignity for patients recovering from severe addiction [PODCAST]](https://kevinmd.com/wp-content/uploads/b3db3337-cf69-4a9b-ad93-f5c4c5d8d499-190x100.jpeg)